Sentinel Node Biopsy in Breast Cancer After Neoadjuvant Therapy in a Latin-American population

Authors

  • Javier Ángel Aristizaba Instituto Nacional de Cancerología
  • Sebastián Quintero Instituto Nacional de Cancerología
  • Alejandro Orozco Instituto Nacional de Cancerología
  • María Claudia Ramírez Instituto Nacional de Cancerología
  • Claudia Cubillos Instituto Nacional de Cancerología
  • Alejandra Sánchez Instituto Nacional de Cancerología
  • Edward Casas Instituto Nacional de Cancerología
  • Cesar Poveda Instituto Nacional de Cancerología
  • Juan Carlos Hidalgo Instituto Nacional de Cancerología
  • Augusto Llamas Olier Instituto Nacional de Cancerología
  • Oscar Alberto Messa Instituto Nacional de Cancerología
  • Erika León Instituto Nacional de Cancerología

Keywords:

Sentinel Lymph Node Biopsy, Axillary clearance, Breast Neoplasms, Neoadjuvant Therapy

Abstract

Objective: To determine the usefulness of sentinel node biopsy in breast cancer after neoadjuvant treatment.
Methods: A study of a diagnostic test.
Results: The analysis was carried out on 67 Latin-American patients treated in the Instituto Nacional de Cancerología (Bogotá, Colombia), obtaining an axillary migration rate of 85%. The sentinel node identification rate was 90%. The false negative rate is 25%. The performance of the diagnostic test shows a sensitivity of 75%, specifity of 100%, positive predictive value of 100%, negative predictive value of 77.5%, and 85.6% accuracy.
Conclusions: The results of our study show that this technique is not recommended as standard procedure, even in patients with clinically negative axilla confirmed by axillary ultrasound. The high percentage of false negatives may be due to the high number of patients with locally advanced disease in our series.

Author Biographies

Javier Ángel Aristizaba, Instituto Nacional de Cancerología

Grupo de Seno y Tejidos blandos, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia

Sebastián Quintero, Instituto Nacional de Cancerología

Grupo de Seno y Tejidos blandos, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia

Fellow Cirugía de Mama y Tumores de Tejidos Blandos, Pontificia Universidad Javeriana, Bogotá, D.C., Colombia

Alejandro Orozco, Instituto Nacional de Cancerología

Grupo de Seno y Tejidos blandos, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia

María Claudia Ramírez, Instituto Nacional de Cancerología

Grupo de Seno y Tejidos blandos, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia

Claudia Cubillos, Instituto Nacional de Cancerología

Grupo de Seno y Tejidos blandos, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia

Fellow Cirugía de Mama y Tumores de Tejidos Blandos, Pontificia Universidad Javeriana, Bogotá, D.C., Colombia

Alejandra Sánchez, Instituto Nacional de Cancerología

Grupo de Seno y Tejidos blandos, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia

Fellow Cirugía de Mama y Tumores de Tejidos Blandos, Pontificia Universidad Javeriana, Bogotá, D.C., Colombia

Edward Casas, Instituto Nacional de Cancerología

Grupo de Seno y Tejidos blandos, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia

Fellow Cirugía de Mama y Tumores de Tejidos Blandos, Pontificia Universidad Javeriana, Bogotá, D.C., Colombia

Cesar Poveda, Instituto Nacional de Cancerología

Servicio Imágenes Diagnósticas, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia

Juan Carlos Hidalgo, Instituto Nacional de Cancerología

Servicio Imágenes Diagnósticas, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia

Augusto Llamas Olier, Instituto Nacional de Cancerología

Grupo de Medicina Nuclear, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia

Oscar Alberto Messa, Instituto Nacional de Cancerología

Grupo de Patología, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia

Erika León, Instituto Nacional de Cancerología

Grupo Área Investigación Clínica, Instituto Nacional de Cancerología, Bogotá, D.C., Colombia

References

Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220(3):391-8.

https://doi.org/10.1097/00000658-199409000-00015

Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelley MC, Ye W, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol. 2000;18(13):2553-9.

https://doi.org/10.1200/JCO.2000.18.13.2553

Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, et al. The sentinel node in breast cancer-a multicenter validation study. N Engl J Med. 1998;339(14):941-6.

https://doi.org/10.1056/NEJM199810013391401

O'Hea BJ, Hill AD, El-Shirbiny AM, Yeh SD, Rosen PP, Coit DG, et al. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg. 1998;186(4):423-7.

https://doi.org/10.1016/S1072-7515(98)00060-X

Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet. 1997;349(9069):1864-7.

https://doi.org/10.1016/S0140-6736(97)01004-0

Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006;106(1):4-16.

https://doi.org/10.1002/cncr.21568

Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15(7):2483-93.

https://doi.org/10.1200/JCO.1997.15.7.2483

Schrenk P, Hochreiner G, Fridrik M, Wayand W. Sentinel node biopsy performed before preoperative chemotherapy for axillary lymph node staging in breast cancer. Breast J. 2003;9(4):282-7.

https://doi.org/10.1046/j.1524-4741.2003.09406.x

Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. 1988;62(12):2507-16.

https://doi.org/10.1002/1097-0142(19881215)62:12<2507::AID-CNCR2820621210>3.0.CO;2-D

Salem A. Sentinel lymph node biopsy in breast cancer: a comprehensive literature review. J Surg Educ. 2009;66(5): 267-75.

https://doi.org/10.1016/j.jsurg.2009.07.011

Balch GC, Mithani SK, Richards KR, Beauchamp RD, Kelley MC. Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer. Ann Surg Oncol. 2003;10(6):616-21.

https://doi.org/10.1245/ASO.2003.05.012

Brady EW. Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer. Breast J. 2002;8(2): 97-100.

https://doi.org/10.1046/j.1524-4741.2002.08205.x

Breslin TM, Cohen L, Sahin A, Fleming JB, Kuerer HM, Newman LA, et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2000;18(20):3480-6.

https://doi.org/10.1200/JCO.2000.18.20.3480

Classe JM, Bordes V, Campion L, Mignotte H, Dravet F, Leveque J, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multi- centric study. J Clin Oncol. 2009;27(5):726-32.

https://doi.org/10.1200/JCO.2008.18.3228

Fernandez A, Cortes M, Benito E, Azpeitia D, Prieto L, Moreno A, et al. Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy scheme. Nucl Med Commun. 2001;22(4):361-6.

https://doi.org/10.1097/00006231-200104000-00003

Haid A, Tausch C, Lang A, Lutz J, Fritzsche H, Peschina W, et al. Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma? Cancer. 2001;92(5):1080-4.

https://doi.org/10.1002/1097-0142(20010901)92:5<1080::AID-CNCR1423>3.0.CO;2-1

Hunt KK, Yi M, Mittendorf EA, Guerrero C, Babiera GV, Bedrosian I, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009;250(4):558-66.

https://doi.org/10.1097/SLA.0b013e3181b8fd5e

Julian TB, Patel N, Dusi D, Olson P, Nathan G, Jasnosz K, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer. Am J Surg. 2001;182(4):407-10.

https://doi.org/10.1016/S0002-9610(01)00736-X

Kang SH, Kang JH, Choi EA, Lee ES. Sentinel lymph node biopsy after neoadjuvant chemotherapy. Breast Cancer. 2004;11(3):233-41.

https://doi.org/10.1007/BF02984543

Lee S, Kim EY, Kang SH, Kim SW, Kim SK, Kang KW, et al. Sentinel node identification rate, but not accuracy, is significantly decreased after pre-operative chemotherapy in axillary node-positive breast cancer patients. Breast Cancer Res Treat. 2007;102(3):283-8.

https://doi.org/10.1007/s10549-006-9330-9

Mamounas EP, Brown A, Anderson S, Smith R, Julian T, Miller B, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005;23(12):2694-702.

https://doi.org/10.1200/JCO.2005.05.188

Miller AR, Thomason VE, Yeh IT, Alrahwan A, Sharkey FE, Stauffer J, et al. Analysis of sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma. Ann Surg Oncol. 2002;9(3):243-7.

https://doi.org/10.1007/BF02573061

Nason KS, Anderson BO, Byrd DR, Dunnwald LK, Eary JF, Mankoff DA, et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer. 2000;89(11):2187-94.

https://doi.org/10.1002/1097-0142(20001201)89:11<2187::AID-CNCR6>3.0.CO;2-#

Newman EA, Sabel MS, Nees AV, Schott A, Diehl KM, Cimmino VM, et al. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation. Ann Surg Oncol. 2007;14(10):2946-52.

https://doi.org/10.1245/s10434-007-9403-y

Schwartz GF, Meltzer AJ. Accuracy of axillary sentinel lymph node biopsy following neoadjuvant (induction) chemotherapy for carcinoma of the breast. Breast J. 2003;9(5):374-9.

https://doi.org/10.1046/j.1524-4741.2003.09502.x

Stearns V, Ewing CA, Slack R, Penannen MF, Hayes DF, Tsangaris TN. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol. 2002;9(3):235-42.

https://doi.org/10.1007/BF02573060

Tafra L, Verbanac KM, Lannin DR. Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer. Am J Surg. 2001;182(4):312-5.

https://doi.org/10.1016/S0002-9610(01)00718-8

Tausch C, Konstantiniuk P, Kugler F, Reitsamer R, Roka S, Pöstlberger S, et al. Sentinel lymph node biopsy after preoperative chemotherapy for breast cancer: findings from the Austrian Sentinel Node Study Group. Ann Surg Oncol. 2008;15(12):3378-83.

https://doi.org/10.1245/s10434-008-0041-9

Yu JC, Hsu GC, Hsieh CB, Yu CP, Chao TY. Role of sentinel lymphadenectomy combined with intraoperative ultrasound in the assessment of locally advanced breast cancer after neoadjuvant chemotherapy. Ann Surg Oncol. 2007;14(1): 174-80.

https://doi.org/10.1245/s10434-006-9132-7

Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006;93(5):539-46.

https://doi.org/10.1002/bjs.5209

Reimer T, Hartmann S, Stachs A, Gerber B. Local treatment of the axilla in early breast cancer: concepts from the National Surgical Adjuvant Breast and Bowel Project B-04 to the planned intergroup sentinel mamma trial. Breast Care [Internet]. 2014 [consulta el 5 de agosto de 2014];9(2):1-1. Disponible en: http://www.karger.com/Journal/Home/231161

https://doi.org/10.1159/000360411

Mamounas EP. Timing of determining axillary lymph node status when neoadjuvant chemotherapy is used. Curr Oncol Rep [Internet]. 2014 [consulta el 5 de agosto de 2014];16(2):364. Disponible en: http://www.current-oncology.com/

https://doi.org/10.1007/s11912-013-0364-y

Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol [Internet]. 2013 [consulta el 5 de agosto de 2014];14(7):609-618. Disponible en: http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70166-9/Abstract

https://doi.org/10.1016/S1470-2045(13)70166-9

Park S, Park JM, Cho JH, Park HS, Kim SI, Park BW. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytologically proven node-positive breast cancer at diagnosis. Ann Surg Oncol [Internet]. 2013 [consulta el 5 de agosto de 2014];20(9):2858-65. Disponible en: http://www.annsurgoncol.org/journals/abstract.html?v=20&j=10434&i=9&a=299210.1245s10434-013-2992-8&doi=

https://doi.org/10.1245/s10434-013-2992-8

Fontein D, van de Water W, Mieog J, Liefers G, van de Velde C. Timing of the sentinel lymph node biopsy in breast cancer patients receiving neoadjuvant therapy-recommendations for clinical guidance. Eur J Surg Oncol (EJSO) [Internet]. 2013 [consulta el 5 de agosto de 2014];39(5):417-24. Disponible en: http://www.ejso.com/article/S0748-7983(13)00255-2/Abstract

https://doi.org/10.1016/j.ejso.2013.02.011

Mamounas EP, Anderson S, Dignam J, Bear H, Julian T, Geyer C, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol [Internet]. 2012 [consulta el 5 de agosto de 2014];30(32):3960-6. Disponible en: http://jco.ascopubs.org/content/30/32/3960.full?sid=4223820b-6026-4b21-9b7b-56ad8c868689

Kelly AM, Dwamena B, Cronin P, Carlos RC. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy -systematic review and meta analysis. Acad radiol. 2009;16(5):551-63.

https://doi.org/10.1016/j.acra.2009.01.026

Ozmen V, Unal ES, Muslumanoglu ME, Igci A, Canbay E, Ozcinar B, et al. Axillary sentinel node biopsy after neoadjuvant chemotherapy. Eur J Surg Oncol. 2010;36(1):23-9.

https://doi.org/10.1016/j.ejso.2009.10.015

Boughey JC, Suman VJ, Mittendorf EA. The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 trial. Cancer Res. 2012;72 24 suppl, abstra94s.

https://doi.org/10.1158/0008-5472.SABCS12-S2-1

Bear HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclop- hosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24(13):2019-27.

https://doi.org/10.1200/JCO.2005.04.1665

How to Cite

[1]
Aristizaba, J.A. et al. 2015. Sentinel Node Biopsy in Breast Cancer After Neoadjuvant Therapy in a Latin-American population. Revista Colombiana de Cancerología. 19, 1 (Mar. 2015), 3–9.

Downloads

Download data is not yet available.

Published

2015-03-01

Issue

Section

Research/original articles